Issue

Vol. 36 No. 10 (2024): Vol 36 Issue 10, 2024

Copyright (c) 2024 T.Sudha Thomas, Lakshmi, sivan

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Design, Synthesis, Characterization, Molecular Docking Studies, In vitro and In vivo Cervical Cancer Activity of Novel N-Substituted Pyrazole Derivatives

https://doi.org/10.14233/ajchem.2024.32021
T. Sudha
Department of Pharmaceutical Chemistry and Analysis, School of Pharmaceutical Sciences, Vels Institute of Science, Technology and Advance Studies (VISTAS), Pallavaram, Chennai-600117, India
https://orcid.org/0000-0001-8821-3999
D. Mahalakshmi
Department of Pharmaceutical Chemistry, Saveetha College of Pharmacy, Saveetha Institute of Medical and Technical Sciences, Chennai-600105, India
https://orcid.org/0000-0002-2394-7366
P. Kumar Nallasivan
Department of Pharmaceutical Chemistry, Karpagam Academy of Higher Education, Coimbatore-641021, India
https://orcid.org/0000-0001-8918-6769

Corresponding Author(s) : P. Kumar Nallasivan

jvchrsty@yahoo.co.in

Asian Journal of Chemistry, Vol. 36 No. 10 (2024): Vol 36 Issue 10, 2024

Abstract

The aim of this study is to design, synthesize, characterize few novel N-substituted pyrazole derivatives and evaluated for their anticancer capabilities; these compounds were selected based on their ability to inhibit the HPV E6 protein. The IR, 1H & 13C NMR, mass spectral and elemental analysis were used to determine the structural details of the newly synthesized substances. The molecular docking was performed using Auto Dock Vina, and the protein-ligand interaction was analyzed using Discovery Studio. The sulforhodamine B (SRB) assay was used to determine the in vitro anticancer activity against the HeLa cell line. Body weight analysis, mean survival time and % increase in life span approaches were used to assess in vivo anticancer effectiveness in Swiss albino mice bearing Dalton’s Lymphoma Ascites (DAL) tumor model. Synthesized compounds have excellent docking energies, according to docking experiments. Compounds I, II and III were selected for anticancer activity in vivo DAL-bearing mice based on the findings of their in vitro and SRB assays exhibiting the antiproliferative activity. Pyrazole derivatives, compounds I and III, demonstrated significant potential as anticancer agents.

Keywords

Pyrazole derivatives Molecular docking Cervical cancer Cancer cell line In vivo anti-tumour activity
Sudha, T., Mahalakshmi, D., & Nallasivan, P. K. (2024). Design, Synthesis, Characterization, Molecular Docking Studies, In vitro and In vivo Cervical Cancer Activity of Novel N-Substituted Pyrazole Derivatives. Asian Journal of Chemistry, 36(10), 2260–2268. https://doi.org/10.14233/ajchem.2024.32021
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX
References
  1. U.T. Sankpal, H. Pius, M. Khan, M.I. Shukoor, P. Maliakal, C.M. Lee, M. Abdelrahim, S.F. Connelly and R. Basha, Tumour Biol., 33, 1265 (2012); https://doi.org/10.1007/s13277-012-0413-4
  2. S. Adel, E. Azab, A. Mohamed, A. Omar, A.M. Alaa, I. Naglaa et al., Eur. J. Med. Chem., 45, 9 (2010).
  3. Y. Gao, K.J. Shen, L. Milane, J. Hornicek, M. Amiji and Z. Duan, Curr. Med. Chem., 22, 1335 (2015); https://doi.org/10.2174/0929867322666150209151851
  4. T. Brzozowski, Curr. Med. Chem., 19, 2 (2012); https://doi.org/10.2174/092986712803414024
  5. S.T. Al-Rashood, I.A. Aboldahab, M.N. Nagi, L.A. Abouzeid, A.A.M. Abdel-Aziz, S.G. Abdel-hamide, K.M. Youssef, A.M. Al-Obaid and H.I. El-Subbagh, Bioorg. Med. Chem., 14, 24 (2006); https://doi.org/10.1016/j.bmc.2006.08.030
  6. F. Sams-Dodd, Drug Discov. Today, 18, 211 (2013); https://doi.org/10.1016/j.drudis.2012.10.010
  7. X. Sun, S. Vilar and N.P. Tatonetti, Sci. Transl. Med., 5, 205 (2013); https://doi.org/10.1126/scitranslmed.3006667
  8. P.N. Dube, S.S. Bule, S.N. Mokale, M.R. Kumbhare, P.R. Dighe and Y.V. Ushir, Chem. Biol. Drug Des., 84, 409 (2014); https://doi.org/10.1111/cbdd.12324
  9. B. Maggio, D. Raffa, M.V. Raimondi, F. Plescia, M.L. Trincavelli, C. Martini, F. Meneghetti, L. Basile, S. Guccione and G. Daidone, Eur. J. Med. Chem., 54, 709 (2012); https://doi.org/10.1016/j.ejmech.2012.06.028
  10. A. Ahmad, H. Varshney, A. Rauf, F.M. Husain and I. Ahmad, J. King Saud Univ. Sci., 26, 290 (2014); https://doi.org/10.1016/j.jksus.2013.09.003
  11. N. Das, A. Verma, P.K. Shrivastava and S.K. Shrivastava, Indian J. Chem., 47B, 1555 (2008).
  12. E.K. Yim and J.S. Park, Cancer Res. Treat., 37, 319 (2005); https://doi.org/10.4143/crt.2005.37.6.319
  13. P.N. Dube, S.S. Bule, Y.V. Ushir, M.R. Kumbhare and P.R. Dighe, Med. Chem. Res., 24, 1070 (2015); https://doi.org/10.1007/s00044-014-1201-z
  14. N.V. Patel and D.J. Sen, Am. J. Adv. Drug Deliv., 1, 2 (2013).
  15. A. Garofalo, L. Goossens, P. Six, A. Lemoine, S. Ravez, A. Farce and P. Depreux, Bioorg. Med. Chem. Lett., 21, 2106 (2011); https://doi.org/10.1016/j.bmcl.2011.01.137
  16. P. Skehan, R. Storeng, D. Scudiero, A. Monks, J. McMahon, D. Vistica, J.T. Warren, H. Bokesch, S. Kenney and M.R. Boyd, J. Natl. Cancer Inst., 82, 1107 (1990); https://doi.org/10.1093/jnci/82.13.1107
  17. A. Monks, D. Scudiero, P. Skehan, R. Shoemaker, K. Paull, D. Vistica, C. Hose, J. Langley, P. Cronise, A. Vaigro-Wolff, M. Gray-Goodrich, H. Campbell, J. Mayo and M. Boyd, J. Natl. Cancer Inst., 83, 757 (1991); https://doi.org/10.1093/jnci/83.11.757
  18. A.E. Eckhardt, B.N. Malone and I.J. Goldstein, Cancer Res., 42, 2977 (1982).
  19. M.P. Sathisha, V.K. Revankar and K.S.R. Pai, Met. Based Drugs, 2008, 362105 (2008); https://doi.org/10.1155/2008/362105
  20. A. Mukherjee, S. Dutta and U. Sanyal, J. Exp. Clin. Cancer Res., 26, 489 (2007).
  21. S. Kameshwaran, V. Suresh, G. Arunachalam, S.K. Kanthlal, M. Mohanraj, Int. Res. J. Pharm., 3, 246 (2012).
Read More
Author biographies is not available.
Statistic
Read Counter : 0 Download : 0